Oncodesign to Develop Experimental Cancer Models for sanofi-aventis
Oncodesign has signed a two-year service contract with sanofi-aventis under which it is to supply and develop exclusive, experimental models in different types of cancer for sanofi-aventis.
Unlike traditional models, which are derived from cultured cell lines, the models that Oncodesign is developing are based on the use of tumor tissue taken directly from patients, enabling more customized evaluations to be made of new therapies while remaining as close as possible to clinical reality. The financial terms of the contract were not disclosed.
"To our knowledge, this contract is a first for a service company, since it is a long-term collaboration that calls for us to supply experimental models to sanofi-aventis," said the CEO of Oncodesign, Philippe Genne. "We are working to develop our design and validation capability so we can make ready-to-use models available to our customers and partners."
Other news from the department business & finance
